Overview

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Status:
Not yet recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of the SHR6390 in combination with anastrozole, pyrotinib, and trastuzumab in patients with ER-positive, HER2-positive breast cancer in the neoadjuvant setting.

Phase:

Phase 2

Details

Lead Sponsor:

Ruijin Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Anastrozole
Trastuzumab